Matt Hewitt
Stock Analyst at Craig-Hallum
(2.69)
# 1,901
Out of 5,114 analysts
40
Total ratings
54.05%
Success rate
3.78%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $18.75 | +92.00% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $7.22 | +66.20% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.58 | +132.56% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $25.07 | +27.64% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $46.84 | +36.64% | 6 | Oct 31, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.67 | +1,396.78% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $17.66 | +69.88% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $1.50 | +366.67% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $162.38 | +23.17% | 3 | Aug 3, 2023 | |
| OABI OmniAb | Initiates: Buy | $10 | $2.09 | +378.47% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $7.23 | +314.94% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.37 | +108,008.11% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $18.75
Upside: +92.00%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $7.22
Upside: +66.20%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.58
Upside: +132.56%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $25.07
Upside: +27.64%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $46.84
Upside: +36.64%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.67
Upside: +1,396.78%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $17.66
Upside: +69.88%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $1.50
Upside: +366.67%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $162.38
Upside: +23.17%
OmniAb
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $2.09
Upside: +378.47%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $7.23
Upside: +314.94%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.37
Upside: +108,008.11%